Pharmaceutics | Free Full-Text | Integrin-αvβ3 as a Therapeutic Target in Glioblastoma: Back to the Future?
Cilengitide | CAS:188968-51-6 | Integrin inhibitor for αvβ3 and αvβ5 | High Purity | Manufacturer BioCrick
Emerging therapeutic opportunities for integrin inhibitors | Nature Reviews Drug Discovery
Cilengitide - Wikipedia
CILENGITIDE | New Drug Approvals
Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma | Journal of Clinical Oncology
Full article: Cilengitide, an αvβ3-integrin inhibitor, enhances the efficacy of anti-programmed cell death-1 therapy in a murine melanoma model
CIPSM - Cilengitide: The First Anti-Angiogenic Small Molecule Drug Candidate. Design, Synthesis and Clinical Evaluation
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial - The Lancet Oncology
The Integrin Inhibitor Cilengitide and Bleomycin-Induced Pulmonary Fibrosis | SpringerLink
![PDF] Integrin inhibitor cilengitide for the treatment of glioblastoma: a brief overview of current clinical results. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/70bc1a06a730e1f512f80dac37d33d6c52a1670a/5-TableI-1.png "PDF] Integrin inhibitor cilengitide for the treatment of glioblastoma: a brief overview of current clinical results. | Semantic Scholar")
PDF] Integrin inhibitor cilengitide for the treatment of glioblastoma: a brief overview of current clinical results. | Semantic Scholar
NEWS RELEASE MDxHealth and Merck KGaA extend Agreement for use of MGMT Assay in Brain Cancer Clinical Trials
Cilengitide inhibits metastatic bone colonization in a nude rat model
Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery | SpringerLink
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial - The Lancet Oncology
Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation. - Abstract - Europe PMC
Frontiers | Cyclic RGD Pentapeptide Cilengitide Enhances Efficacy of Gefitinib on TGF-β1-Induced Epithelial-to-Mesenchymal Transition and Invasion in Human Non-Small Cell Lung Cancer Cells
Cilengitide trifluoroacetate | 99.8%(HPLC) | In Stock | Integrin inhibitor
Iceni Pharmaceuticals Launches as New Specialist in Cancer Therapies
IJMS | Free Full-Text | Combination Effect of Cilengitide with Erlotinib on TGF-β1-Induced Epithelial-to-Mesenchymal Transition in Human Non-Small Cell Lung Cancer Cells
Cilengitide | C27H40N8O7 | CID 176873 - PubChem
Cilengitide
Cilengitide: an RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignancies | Future Oncology
